Camberlogo (Camberlogo)
Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71335-2535
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2535). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (Figure 1)
The text provides information on the percent reduction in the CPS rate for Divalproex Sodium Delayed Release Tablets compared to placebo. The exact reduction percentage is indicated as approximately 3191%.*
Figure-2 (Figure 2)
This text indicates the percentage reduction in the CPS (Child Protective Services) rate. It represents a measure of the decrease in the frequency of child protection service reports or cases.*
Figure-3 (Figure 3)
Label (Lbl713352535)
Each extended-release tablet contains Divalproex Sodium, USP equivalent to valproic acid 500 mg. This medication should be stored in a tight, light-resistant container at room temperature with excursions permitted to a certain range. Keep it out of reach of children and do not accept if the seal over the bottle opening is broken or missing. It is essential to dispense the Medication Guide to each patient when prescribing this medication. For more information, refer to the provided link.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
